Table 1 Baseline patient characteristics
From: Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes
Demographics | EZ/Simva 10/20 (N = 93) | Simva 40 (N = 106) |
|---|---|---|
Age, yrs mean (SD) | 62.8 (7.9) | 62.9 (7.1) |
Females | 42 (45%) | 36 (34%) |
Body mass index, kg/m2, mean (SD) | 73.7 (11.6) | 75.1 (12.7) |
Current smokers | 16 (17.2%) | 21 (19.8%) |
Hypertension | 58 (62.4%) | 56 (52.8%) |
Diabetes | 37 (39.8%) | 50 (47.2%) |
Laboratory values mean (SD) | ||
LDL-C (mmol/L) | 3.27 (0.47) | 3.29 (0.44) |
TC (mmol/L) | 5.18 (0.58) | 5.18 (0.56) |
HDL-C (mmol/L) | 1.26 (0.30) | 1.19 (0.26) |
TC/HDL-C | 4.31 (1.03) | 4.54 (1.00) |
Triglycerides (mmol/L) | 1.45 (0.62) | 1.52 (0.59) |
AST (U/L) | 19.8 (5.3) | 20.6 (4.7) |
ALT (U/L) | 22.7 (9.5) | 25.5 (9.7) |
CK (U/L) | 97.0 (44.1) | 110.7 (46.2) |
Prevalence of cardiovascular diseases, n (%) | ||
Cerebrovascular disease | 30 (32.3%) | 30 (28.3%) |
Peripheral vascular disease | 32 (34.4%) | 39 (36.8%) |
Ischemic heart disease | 40 (43.0%) | 49 (46.2%) |